Newsroom December 18, 2023 Avstera Therapeutics Announces FDA Clearance of IND Application for AVS100, a Novel Highly Selective HDAC6 Inhibitor Targeting Solid Tumors November 11, 2022 Avstera Therapeutics Receives FDA Orphan Drug Designation on AVS100 for Treatment of Advanced Stage Melanoma November 9, 2022 Avstera Therapeutics Closes Seed Round to Advance its Lead Programs Targeting Solid Tumors
